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P. Britton b. aOncology Centre, Cambridge University Hospitals NHS
Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK. bCambridge
Breast Unit, Cambridge University Hospitals NHS Foundation Trust,
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University of Warwick, Coventry CV4 7AL, UK. dCambridge Cancer
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Background: Pathologic complete response (pCR) is an impor-
tant predictor of long term survival in patients with breast cancer
receiving neoadjuvant chemotherapy.
Methods: Unidimensional and volumetric ultrasound mea-
surements prior to, after 4 cycles (mid-treatment), and at the
end of 8 cycles (end-treatment) of chemotherapy were available
from a subset of 55 patients enrolled in Neo-tAnGo, a phase III
neoadjuvant chemotherapy trial. Changes in proportional lon-
gest diameter (LD) and volume as well as absolute residual size
thresholds were examined for their ability to predict pCR or
pCR plus minimal residual disease (pCR/MRD). Sensitivity, spec-
ificity, positive (PPV) and negative predictive values (NPV) and
likelihood ratios (LRs) were calculated. Receiver–operator char-
acteristic (ROC) curves and logistic regression models were
constructed.
Results: At mid-treatment, neither complete radiological
response, nor proportional LD or volume changes were found pre-
dictive of final pCR. Residual tumour volume 61 cm3 was associ-
ated with pCR/MRD (p = 0.014). Sensitivity, specificity, PPV, NPV,
LR+ and LR– values were 61%, 77%, 61%, 77%, 2.62 and 0.51 respec-
tively. The area under the ROC curve (AUC) was 0.689 (p = 0.03).
Volume 61 cm3 was found significant in a univariate logistic
regression (p = 0.011), but not in multivariate analysis. At end-
treatment, no ultrasound measurements were found predictive
of pCR or pCR/MRD.
Conclusions: Proportional tumour size changes were not found
predictive of good pathologic response, yet residual volume
61 cm3 after 4 cycles of chemotherapy was found predictive. Mul-
tiple volume and LD thresholds were examined and uncorrected
p-values presented, increasing the possibility of type I errors. Rep-
lication in an independent dataset is required.
doi:10.1016/j.ejcsup.2010.06.032
O-32 D-DIMER AS A MARKER FOR EARLY PROGRESSION IN
PATIENTS COMMENCING NEOADJUVANT CHEMOTHERAPY
C.C. Kirwan, C.N. McCollum, N.J. Bundred, G.J. Byrne. University
Department of Surgery, University Hospital of South Manchester, UK
Objective: D-dimer, the end product of coagulation, is increased
pre-operatively in abdominal cancers with poor prognosis, and in
early breast cancer is associated with lymph node positivity. How-
ever, d-dimer as a marker of response to treatment has not been
investigated.
Methods: In early breast cancer patients receiving neoadjuvant
chemotherapy (n = 11), d-dimer was measured prior to com-
mencement of chemotherapy and at 6 months following com-
mencement of treatment. Clinical and radiological follow-up of
breast cancer was at 3, 6, 12 and 24 months. We compared base-
line d-dimer, d-dimer at 6 months, and change in d-dimer in
response to treatment in patient with relapse compared to those
remaining disease free at 2 years.
Results:
Relapse at
2 years
Disease free at
2 years
P-value
D-dimer pre-
chemotherapy,
ng/ml (SD) (n)
1328 (1183) (3) 259 (91) (7) 0.03
D-dimer at
6 months,
ng/ml (SD) (n)
1364 (221) (2) 454 (224) (5) 0.005
Change in
d-dimer in
response to
chemotherapy,
ng/ml (SD) (n)
717 (345) (2) 177 (188) (5) 0.04
(Upper limit of normal 500 ng/ml).
No patients had clinical evidence of relapse at 6 months.
Conclusions: Despite no clinical evidence of disease, d-dimer
remains elevated at 6 months following breast cancer treatment
in patients with early relapse. D-dimer, prior to treatment and fol-
lowing treatment, may act as a marker for early relapse in breast
cancer.
doi:10.1016/j.ejcsup.2010.06.033
O-33 AN ARTIFICIAL NEURAL NETWORK BASED ALGORITHM
FOR PREDICTING CONTINUOUS TIME TO EVENT DATA IN
BREAST CANCER
Lee Lancashire, Andy Sutton, Robert Rees, Graham Ball.
Campandia Ltd/Nottingham Trent University, Nottingham, UK
Introduction: Development of gene signatures usually focuses on
changing timedependent data into binary categories, for example 5
year survival. Predicting actual time to an event has thepotential to
be much more powerful. Here we introduce a novel algorithm
termedRiskDistiller that aims toovercome the splitting of data into
arbitrary categories by using artificial neural networks to predict a
continuous response variable describing the actual time to event.
Methods: Time to recurrence data (0–14 years) for a series of
breast cancer patients was made available in a study described
by Van de Vijver et al. We applied our method to those cases with
known events to identify an optimal panel of genes with the abil-
ity to predict the actual time to recurrence. The gene signature
started as a single gene and was grown upwards until the optimal
model was determined.
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Results: The optimal signature contained 28 genes. Therewas a
statistically significant correlation between actual versus pre-
dicted time to recurrence for blind data (rho = 0.975; p < 0.0001).
A prospective Kaplan–Meier plot was generated which showed
no significant difference to the actual Kaplan–Meier plot for this
dataset (p > 0.955).
Discussion: For the first time gene expression signatures have
been identified that predict actual time to event data rather than
placing patients into arbitrary risk groups. Coupled with the abil-
ity to derive prospective Kaplan–Meier plots, this tool has the
potential for assessing prognosis and determining treatment reg-
imens on a case by case basis.
doi:10.1016/j.ejcsup.2010.06.034
O-34 DYNAMIC CONTRAST-ENHANCED MRI REVEALS CORE
SIGNALLING PATHWAYS IN BREAST CANCER
S. Mehta a,N.P.Hughes b,d, F.M. Buffa a, R.F.Adamsc, S.S. Gambhir b,e,
A.L. Harris a. aWeatherall Institute of Molecular Medicine, Oxford,
UK. b Institute of Biomedical Engineering, University of Oxford,
Oxford, UK. cOxford Breast Imaging Centre, Churchill Hospital,
Oxford, UK. dMolecular Imaging Program, Stanford University,
USA. eDepartment of Bioengineering, Stanford University, USA
Dynamic contrast-enhanced MRI (DCE-MRI) is a widely used
imaging modality for the management of breast cancer patients.
At present, there is little understanding of how imaging patterns
on DCE-MRI relate to the molecular pathways that drive tumour
growth.
To address this issue, we performed a retrospective study of 65
patients with primary breast cancer, for whom pre-treatment
DCE-MRI scans and formalin fixed paraffin embedded (FFPE) core
biopsies were available. We used pharmacokinetic modelling of
DCE-MRI to quantify the rate constant kep governing contrast
agent washout from the tumour extravascular extracellular
space. By computing the median kep over tumour volume an
overall tumour leakiness score was derived. We extracted RNA
from FFPE cores and measured gene expression using Affymetrix
Human Plus 2.0 arrays. Following normalization and pre-process-
ing, we used permutation tests to determine which genes were
significantly correlated with median kep. Pathway analysis was
performed using GeneCodis with the KEGG database.
Setting the False Discovery Rate to 5% resulted in 1258 genes
that were significantly positively correlated with tumour leaki-
ness including integrins B1 and A6, TGFBR1, HIF1 and 2A, SMAD4,
HES1, JAG1. Interestingly, pathway analysis revealed that the p53
(P < 0.004), Wnt (P < 0.004) and Notch signalling pathways
(P < 0.006), which are known to have important roles in angiogen-
esis, were all significantly associated with tumour leakiness.
These results illustrate how the combination of non-invasive
imaging and gene expression profiling can reveal the molecular
correlates of radiological features and provide insight into the
mechanisms driving tumour growth and angiogenesis.
doi:10.1016/j.ejcsup.2010.06.035
O-35 SERPINB3, A BIOMARKER OF TAXANE BENEFIT IN BREAST
CANCER
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Iain Miller b, Steve Heys a. aCancer Medicine, University of Aberdeen,
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Background: Lysosomal cathepsin proteases function in a pro-
grammed cell death (LPCD) pathway. Although there is evidence
for the importance of this pathway in cancer cell survival, it has
not been exploited in anti-cancer therapeutics. Hsp70 and ser-
pinB3 can block this pathway and promote cell survival. Further-
more, serpinB3 is associated with lack of response to
chemotherapy. Cathepsin mediated cell death is observed in
response to anthracyclines or taxanes, which are widely utilised
in breast cancer treatment.
Methods: We evaluated serpinB3 and Hsp70 by immunohisto-
chemistry in 255 surgically resected breast tumours from patients
treated with either CVAP or CVAP and docetaxel prior to poten-
tially curative resection. The study was performed with the
approval of the regional research ethics committee.
Results: SerpinB3 and Hsp70 were significantly correlated with
poor pathological response (P = 0.014 and P < 0.0001, respectively).
SerpinB3 positivity is a poor prognostic factor (P = 0.029; mean
survival 88.8 vs. 100.4 months) and this is independent in multi-
variate analysis (P = 0.023). Patients with serpinB3 positive
tumours have poor survival if treated with anthracycline
(P = 0.026) but not if they are also given a taxane (P = 0.786). Fur-
thermore, only patients with serpinB3 positive tumours benefit
from taxane treatment (P = 0.008).
Conclusions: SerpinB3 and Hsp70 are predictive biomarkers,
potentially blocking breast tumour response to chemotherapy
by preventing LPCD. SerpinB3 is prognostic and may prevent
anthracycline-, but not taxane-, mediated cytotoxicity in breast
tumours. Patients with serpinB3 negative tumours have a good
prognosis when treated with anthracycline-based therapy alone.
In contrast, patients with serpinB3 positive tumours benefit sig-
nificantly from the addition of docetaxel.
doi:10.1016/j.ejcsup.2010.06.036
O-36 RECRUITMENT OF INSULIN RECEPTOR SUBSTRATE-1 BY
ErbB3 IMPACTS ON IGF-IR SIGNALLING IN OESTROGEN RECEP-
TOR-POSITIVE BREAST CANCER CELLS
J.M. Knowlden a, J.M.W. Gee a, D. Barrow b, J.F. Robertson b, I.O.
Ellis b, R.I. Nicholson a, I.R. Hutcheson a. aTenovus Centre for Cancer
Research, Cardiff University, UK. b Professorial Unit of Surgery,
Nottingham City Hospital, Nottingham, UK
We have shown that insulin receptor substrate 1 (IRS-1) can
associate with epidermal growth factor receptor (EGFR), with acti-
vation of EGFR promoting recruitment and phosphorylation of
IRS-1 in an oestrogen receptor (ER)-positive tamoxifen resistant
breast cancer (BC) cell line. In this study, we examined recruit-
ment of IRS-1 by another erbB receptor family member, erbB3 in
three ER-positive BC cell lines. Our studies revealed an interaction
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